Impact of the treatment of chronic myeloid leukaemia by tyrosine-kinase inhibitors on sick leaves refund: a nationwide cohort study.

Background: The advent of chronic myeloid leukaemia (CML) tyrosine-kinase inhibitors (TKI) has led to new paradigms including occupational rehabilitation.

Objectives: This study aimed to characterize the impact of CML treatment on sick leaves within the 2 years following diagnosis in working-age patients.

Methods: A cohort of all 18-60-year-old newly diagnosed CML patients initiating a TKI between January 1 2011 and December 31 2014 in France was identified in the French National Healthcare database (Système National des Données de Santé [SNDS]).

Diabetes Remission and Relapse After Bariatric Surgery: a Nationwide Population-Based Study.

Purpose: The long-term impact of bariatric surgery on the remission of type 2 diabetes (T2DM) remains to be clarified through large nationally representative cohorts. The objectives were to determine the incidence of T2DM remission and relapse after bariatric surgery, to determine the factors associated with remission and to establish a profile for patients at risk for relapse.

Materials And Methods: We conducted a population-based cohort study using data from the French national health insurance database (Systeme national des données de santé [SNDS]).

Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial.

Background And Purpose: Non-motor symptoms (NMS) of Parkinson's disease (PD) have a major impact on health-related quality of life. This is the first randomized controlled trial to use the NMS Scale (NMSS) as a primary outcome to assess treatment effects on NMS in PD.

Methods: In this double-blind trial (NCT01300819), patients with PD and a total NMSS score ≥40 were randomized (2:1) to rotigotine or placebo, titrated over 1-7 weeks to optimal dose (≤8 mg/24 h for patients not receiving levodopa, ≤16 mg/24 h for patients receiving levodopa), maintained for 12 weeks.

Parkinson disease: Can a new trial end controversy over when to use levodopa?

Levodopa is the standard therapy for Parkinson disease, but prolonged use promotes the development of adverse motor effects. A new trial compared the effectiveness of levodopa administration early in the disease with therapies that used alternative dopaminergic agents before levodopa. No clinically relevant differences were found between the treatment strategies.